Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(75.0%)
N/A
1(25.0%)
4Total
Phase 2(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT03800160Enrolling By Invitation

Greater China Metabolic and Bariatric Surgery Database

Role: collaborator

NCT06022445Unknown

Prospective Validation of CARPET Prognostic Model for Septic Shock After Allo-HSCT

Role: collaborator

NCT03532893Completed

Predictive Value of Inflammatory Biomarkers and FEV1 for COPD

Role: collaborator

NCT02621333Phase 2Terminated

Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma

Role: collaborator

NCT03647384Phase 2Unknown

Guilingji Capsule for Mild-to-moderate Cognitive Impairment

Role: collaborator

NCT02560441Phase 2Unknown

Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

Role: collaborator

NCT02696551Not ApplicableUnknown

Impact of Medical Education of Physician Action 2

Role: lead

All 7 trials loaded